Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Modalis (ticker 4883) is a drug-discovery venture advancing R&D into gene-regulating therapeutics using CRISPR-GNDM® technology. While preparing primarily for the IND filing and clinical-trial launch for MDL-101, the company is exploring opportunities including business partnerships, joint development and licensing agreements for its proprietary-model pipeline. With cash on hand of ¥3,015.530 million (translated from thousands of yen), the company expects to secure sufficient funds to continue operations for the next year. As the business consists of a single segment, the gene-therapy drug development business, segment information is omitted.
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.